Journal
NEUROLOGIA I NEUROCHIRURGIA POLSKA
Volume 51, Issue 3, Pages 221-226Publisher
ELSEVIER URBAN & PARTNER SP Z O O
DOI: 10.1016/j.pjnns.2017.03.002
Keywords
BDNF; MS; Natalizumab
Categories
Funding
- European Social Fund, Human Resources Development Operational Programme [POSDRU/159/1.5/138776]
Ask authors/readers for more resources
Aim of the study: Our main purpose was to investigate if the chronic treatment with the disease-modifying drug natalizumab shows quantifiable effect on BDNF levels in multiple sclerosis patients. Materials and Methods: BDNF plasma concentration was evaluated using enzyme-linked immunosorbent assay in healthy individuals, not treated multiple sclerosis patients and patients treated with natalizumab. Results: Multiple sclerosis patients have a significantly lower amount of peripheral BDNF than healthy individuals. Patients treated with natalizumab have significantly higher BDNF levels than not treated patients. Conclusions: Chronic natalizumab treatment is associated with significantly increased plasma BDNF concentration in multiple sclerosis. (C) 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available